Pancreatic Adenocarcinoma
Conditions
Keywords
Pancreatic Adenocarcinoma, Pancreatic Cancer, PCX12, IL-12
Brief summary
The purpose of this study is to determine whether a new treatment combining radiation therapy with PCX12 is safe and tolerable.
Detailed description
Single center, open label, escalating dosage of PCX12 with standard of care practice for subjects who are diagnosed with adenocarcinoma of the head of the pancreas. Subjects with undergo standard of care radiation therapy and then start on PCX12 therapy starting at 200 ng/kg of PCX12 escalating to a potential maximum dosage of 800 ng/kg of PCX12 with adjacent tolerability and safety guidelines.
Interventions
DRUGPCX-12
treatment combining radiation therapy with PCX12
Sponsors
Haoming (Carl) Qiu
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with pathologically proven diagnosis of adenocarcinoma of the pancreas * After chemotherapy, tumor is determined to be either locally advanced or unresectable by hepatobiliary surgeon; or tumor is considered potentially resectable but subject does not proceed with surgical resection for any reason * Have completed first line chemotherapy without progression or non-regional metastases * Tumor is radiographically evident on CT scan after chemotherapy * Tumor is anatomically amenable to SBRT, e.g. does not directly invade the stomach or bowel * Tumor is amenable to intra-tumor injection under endoscopic ultrasound guidance * ECOG performance status 0-2 * Patients with childbearing potential must demonstrate a negative urine or serum pregnancy test * Male or female subjects, aged at least 18 years; Female subjects of childbearing potential may participate if adequate contraception is used during, and for at least the three months after study completion; Male subjects with partners of childbearing potential may participate in the study if they had a vasectomy at least 6 months prior to randomization or if adequate contraception is used during, and for at least the three months after study completion; Adequate contraception is defined as resulting in a failure rate of less than 1% per year * Patient must be able to understand and willingly sign study specific informed consent prior to study entry * Anticipated life expectancy ≥ 12 weeks * Patients aged at least 18 years of age
Exclusion criteria
* Progression of disease or metastatic disease after first line systemic therapy * Prior radiation treatment or surgical resection of any pancreatic malignancy * Inability to tolerate SBRT, Endoscopic ultrasound or IL-12 Injection procedure * Lack of radiographically evident disease after first line chemotherapy * Severe, active comorbidity that shortens the patient's life expectancy to less than 12 weeks * History of past malignancy * Patient who is pregnant and/or breastfeeding * Inability to comply with other required protocol procedures including required biopsies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) | 3 years | The Primary objective of the safety lead in component is to report acute, attributable, gastrointestinal toxicity |
| Maximum tolerable dose [Safety and Tolerability] | 3 years | Maximum tolerable dose is defined by less than or equal to 30% dose limiting toxicity (DLT) event rate within a given dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of radiographic response | 2 months | This study will assess radiographic response following SBRT and PCX12 utilizing RECIST 1.1 criteria |
| Change in biomarkers of innate and adaptive immunity | baseline and 4 weeks | A combination of flow/mass cytometry will be employed to assess intratumoral immune cells before and after treatment. Specifically, cells of the adaptive immune system, namely B and T cells (both CD4+ and CD8+), along with innate cells including monocytes, macrophages, neutrophils, and natural killer cells will be investigated and percent of total CD45+ cells along with absolute cell number will be tabulated. Additionally, markers of activation (IFNg, TNF, etc.) along with suppression (PD1, PD-L1, LAG3, etc.) will be included in the panel of analysis. |
Countries
United States
Contacts
CONTACTHaoming Qiu
PRINCIPAL_INVESTIGATORHaoming Qiu
University of Rochester
Outcome results
None listed